Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about ROCHE HOLDING LTD.
01/23 ROCHE : Students tour Sweetwater Spectrum gardens
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
01/22 Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
01/22 New drugs recast $10 billion haemophilia market as Sanofi swoops in
01/22 ABCAM : signs licensing deal with Roche; shares rise
01/21 ROCHE : College basketball
01/15 BIOGEN : Roche's Ocrevus receives EU approval for MS
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 ROCHE : OCREVUS (ocrelizumab) approved in the European Union for relapsing forms..
01/12 ROCHE : Niger to Screen 1 Million Cancer Patients, Treat 20 Diagnosed Cases Annu..
01/12 ROCHE : OCREVUS (ocrelizumab) approved in the European Union for relapsing forms..
01/10 FOUNDATION MEDICINE : Roche, Syapse explore AI-based tech for cancer precision m..
01/10 ROCHE : Personalised medicine and partnering - key areas for Ferring
01/10 ROCHE : commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per ..
01/08 SHIRE : cuts 2020 revenue target, prepares for spin-off of ADHD drugs
More most relevant news
All news about ROCHE HOLDING LTD.
01/23 ROCHE : Students tour Sweetwater Spectrum gardens
01/23 ROCHE : Abcam acquires rights to over 700 Roche products in new licensing deal
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
01/22 Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
01/22 New drugs recast $10 billion haemophilia market as Sanofi swoops in
01/22 ABCAM : signs licensing deal with Roche; shares rise
01/21 ROCHE : College basketball
01/20 EXTENSION OF THE EXTRACURRICULAR ACT : flexible floor, following unsuccessful co..
01/19 SYNDAX PHARMACEUTICALS : Announces Clinical Collaboration to Evaluate Entinostat..
01/19 FOUNDATION MEDICINE : Reports Preliminary 2017 Results
More news
Sector news : Pharmaceuticals - NEC
08:16a NOVARTIS : Correction to Novartis Earnings Article
08:15a SANOFI : Sees Currency Effects Negatively Impacting 4Q Sales
08:10a NOVARTIS : 4Q Profit Rises, Buoyed by Sales of New Drugs -- Update
07:51a NOVARTIS : 4Q Profit Rises, Buoyed by Sales of New Drugs
01:42a P&G's Price Cuts Ripple Through Consumer Products -- 2nd Update
01/23 JOHNSON & JOHNSON : Results Driven by Pharmaceutical Sales Growth -- 3rd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/23 Ionis Pharmaceuticals Is Poised To Disrupt Biotech
01/23 YOUR DAILY PHARMA SCOOP : Omeros' OMS721, Celgene To Acquire Juno, BioCryst And ..
01/21 CLEMENTIA : A Game Changer In The Rare Disease Market Trading At Low Multiples T..
01/20 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
01/19 Key events next week - healthcare
01/19 Roche's Tecentriq OK'd in Japan for lung cancer
Latest Tweets
01/23Novartis and Roche lose a key battle over antitrust fines in Italy..  
01/23TREND REVERSAL DOWN ALERT: $SENS SENSEONICS HOLDINGS INC ? TradeIdeas via  
01/23Polyphor: Global No. 2 in the 2018 Antimicrobial Resistance Benchmark publish.. 
01/23Mag Roche's Braised Beef Cheek with Creamy Mash -  
01/23"We see healthy growth and that is reducing the danger of some sudden crisis...
1
More tweets
Qtime:164
Financials ( CHF)
Sales 2017 53 457 M
EBIT 2017 18 232 M
Net income 2017 11 159 M
Debt 2017 9 887 M
Yield 2017 3,63%
P/E ratio 2017 17,69
P/E ratio 2018 16,21
EV / Sales 2017 4,00x
EV / Sales 2018 3,77x
Capitalization 204 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 273  CHF
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-4.34%213 485
JOHNSON & JOHNSON5.47%397 981
NOVARTIS1.29%226 840
PFIZER1.99%220 129
MERCK AND COMPANY8.90%167 050
AMGEN8.84%139 614